Skip to main content
Ocumension Therapeutics logo

Ocumension Therapeutics — Investor Relations & Filings

Ticker · 1477 ISIN · KYG674111011 LEI · 5493000USURI3SIL4Z85 HKEX Manufacturing
Open in API
Filings indexed 460 across all filing types
Latest filing 2023-06-16 Declaration of Voting R…
Country KY Cayman Islands
Listing HKEX 1477

About Ocumension Therapeutics

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company dedicated to the research, development, and commercialization of first-in-class or best-in-class therapeutics. The company focuses on providing comprehensive treatment solutions for Chinese patients suffering from ocular diseases. Ocumension has established a complete ophthalmic drug product line, currently holding 20 drug assets covering both anterior and posterior segments of the eye. Its portfolio addresses major conditions such as chronic non-infectious uveitis, infective and allergic conjunctivitis, and diabetic macular edema. The company employs a strategy combining continuous scientific innovation, independent R&D, and strategic alliances to sustain the supply of innovative products across the ophthalmology field.

Recent filings

Filing Released Lang Actions
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 16, 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the poll results from the Annual General Meeting (AGM) held on June 16, 2023. It details the voting outcomes on various resolutions including adoption of financial statements, re-election of directors, appointment of auditors, and share issuance mandates. The document does not contain the full financial statements or detailed reports but rather the official voting results. It explicitly references the Notice and Circular for full details, indicating this is a formal announcement of voting results rather than the AGM materials themselves or the full annual report. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (6088 characters) and content support this classification with high confidence.
2023-06-16 English
VOLUNTARY ANNOUNCEMENT PATIENT ENROLLMENT COMPLETED IN THE GLOBAL MULTI-CENTER PHASE III CLINICAL TRIAL OF OT-101
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ocumension Therapeutics regarding the completion of patient enrollment in a global multi-center Phase III clinical trial for a drug (OT-101). It provides business updates and clinical trial progress but does not contain financial statements, regulatory certifications, or detailed financial data. The document is relatively short (3921 characters) and serves as a business update rather than a formal financial or regulatory report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an announcement of a business development event, which aligns best with the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2023-06-01 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 May 2023
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly report on movements in securities, specifically focusing on the issuance and changes in share capital, share options, warrants, and other share-related activities for Ocumension Therapeutics. It includes detailed tables on authorized and issued shares, share options exercised, warrants issued, and confirmations related to compliance with listing rules. The document is addressed to the Hong Kong Exchanges and Clearing Limited and references specific listing rules (Chapter 19B of the Exchange Listing Rules). It is a regulatory submission about share capital movements rather than a financial report, earnings release, or management discussion. It does not contain financial statements or earnings data but focuses on share issuance and capital changes. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA).
2023-06-01 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and/or share buybacks for Ocumension Therapeutics. It details the exercise of share options by a director, the number of shares issued, issue price, and closing balance of shares. The document references compliance with listing rules of the Stock Exchange of Hong Kong and confirms authorization by the board. This is a regulatory disclosure about share capital changes, specifically about share issuance due to option exercise. It is not a full financial report, earnings release, or management discussion. It fits the category of announcements regarding share capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length (7420 characters) and detailed data support it being a substantive disclosure rather than a brief announcement or certification.
2023-05-08 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 April 2023
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly return report on movements in securities, specifically focusing on share capital, issued shares, share options, warrants, and other share-related movements for Ocumension Therapeutics. It includes confirmations related to the authorization and compliance of these share issuances. The document is submitted to the Hong Kong Exchanges and Clearing Limited and references specific listing rules (Chapter 19B of the Exchange Listing Rules). It is not a financial report, earnings release, or management discussion but rather a regulatory filing about share capital changes and securities movements. This type of document fits best under the category of Share Issue/Capital Change (SHA), as it details changes in share capital and issuance activities.
2023-05-05 English
VOLUNTARY ANNOUNCEMENT INCLUSION OF OT-1001 IN THE PRIORITY REVIEW AND APPROVAL PROCESS OF THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ocumension Therapeutics regarding the inclusion of their drug OT-1001 in the priority review and approval process by the National Medical Products Administration (NMPA) of China. It provides a business update about regulatory progress and potential commercialization but does not contain financial statements, detailed financial analysis, or comprehensive report content. The document is relatively short (3221 characters) and serves as an announcement to inform shareholders and investors about a specific business development. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing in the sense of compliance or certification, nor is it a voting result or capital change. The best fitting category is a general Regulatory Filing (RNS) as it is a regulatory announcement about drug approval status without detailed financial data or report content.
2023-04-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.